小剂量尿激酶联合蚓激酶治疗急性进展性脑梗死临床研究

Clinical Study on Low Dose of Urokinase Combined with Lumbrokinase in the Treatment of Acute Progressive Cerebral Infarction

目的:研究小剂量尿激酶联合蚓激酶治疗急性进展性脑梗死的临床效果。方法:将恩平市人民医院2015年2月-2016年6月收治的60例急性脑梗死患者按照随机数字表法分为对照组与治疗组,每组各30例。对照组采用蚓激酶治疗,治疗组采用小剂量尿激酶联合蚓激酶治疗。比较两组患者神经功能缺损程度、日常生活能力、治疗效果。结果:治疗后两组患者NIHSS、ADL评分均降低,但对照组治疗后NIHSS、ADL评分(18.3±4.7)分、(13.3±1.8)分均高于治疗组(11.6±3.5)分、(11.4±1.6)分,且对照组治疗总有效率(73.3%)低于治疗组(93.3%),比较差异均有统计学意义(P<0.05)。结论:给予急性进展性脑梗死患者小剂量尿激酶联合蚓激酶治疗效果显著,能有效改善患者神经功能,提高生活质量。

Objective：To study the clinical effect on low dose of Urokinase combined with Lumbrokinase in the treatment of acute progressive cerebral infarction（APCI）.Method：60 APCI patients admitted into the Enping People＇s Hospital from February 2015 to June 2016 were randomly divided into control group of 30 cases which took lumbrokinase and treatment group of 30 cases which took low dose of Urokinase combined with Lumbrokinase.The degree of nervous functional defect,activity of daily living（ADL） and curative effect of two groups were compared.Result：After treatment,the NIHSS and ADL scores of two groups decreased,while the control group of NIHSS and ADL score were respectively（18.3±4.7） scores and（13.3±1.8） scores higher than the treatment group of（11.6±3.5） scores and（11.4±1.6） scores;the total effective rate of control group was 73.6% lower than treatment group of 93.3%,the differences were statistically significant（P〈0.05）.Conclusion：Low dose of Urokinase combined with Lumbrokinase for treating APCI patients have significant curative effect,which can effectively improve patients＇ neurologic function and increase living of quality.